Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | INCB054329 |
Synonyms | |
Therapy Description |
INCB054329 is BET inhibitor, which inhibits cell proliferation (Proceedings of the 106th Annual Meeting of the AACR; 2015; Abstract nr 3525). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB054329 | INCB-054329 | BET Inhibitor (Pan) 30 | INCB054329 is BET inhibitor, which results in decreased expression of BET protein-regulated genes including MYC, potentially leading to decreased tumor cell proliferation (PMID: 30206163) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | colorectal cancer | not applicable | INCB054329 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, INCB054329 promoted apoptosis and decreased MYC expression in colorectal cancer cell lines in culture and demonstrated anti-tumor activity in colorectal cancer cell line xenograft models (AACR; 2015. Abstract nr 3525). | detail... |
Unknown unknown | multiple myeloma | not applicable | INCB054329 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, INCB054329 treatment reduced MYC expression and proliferation of myeloma cell lines in culture, and inhibited tumor growth in myeloma cell line xenograft models (PMID: 30206163). | 30206163 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02431260 | Phase I | INCB054329 | An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies | Terminated | USA | 0 |